Josh Michaud Profile picture
Mar 6, 2020 9 tweets 7 min read Read on X
To those new here or just following me,
I’m an infectious disease epidemiologist by training @JohnsHopkinsSPH with an interest and additional education in #vaccine science and disease modeling.
Before @KFF, I worked as an epidemiologist @HopkinsMedicine & @BMore_Healthy, first in #STD / #HIV prevention, then acute communicable diseases and #publichealth preparedness (after 9/11 and the 2001 anthrax mailings).
My PhD @SAISHopkins focused on international cooperation on emerging infectious disease surveillance, reporting, and response. I examined in detail the cases of #HIV/AIDS, drug-resistant #TB, #SARS, and pandemic #flu.
Then, as an epidemiologist @DeptofDefense I assessed infectious disease risk for the US military, everything from pandemic #influenza, to #malaria and #dengue, to #Ebola and leishmaniasis.
In 2010, I joined @KFF (no connection to Kaiser Permanente) #globalhealth team, with a focus on the U.S. government role. We often look at science and policy around outbreaks (like #Ebola, #Zika, and now #COVID19).
[follow my wonderful @KFF expert colleagues for global health and coronavirus insights: @jenkatesdc & @KellieMossGH]
Since 2009, I have also taught (co-taught for the last few years) graduate courses @SAISHopkins, including a course on public health and development, and another on global health policy.
So hello to new followers! Watch this space for more on #COVID19 #coronavirus and other global health analysis. Ask me anything.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Josh Michaud

Josh Michaud Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @joshmich

Sep 30, 2022
Starting to get a sense of the public's understanding of, and demand for, the new bivalent Covid booster:

-1/2 of adults have heard little or nothing about the new booster

-4 in 10 fully vaccinated adults not sure if CDC recommends the booster for them

kff.org/coronavirus-co…
Results from a new @KFF vaccine monitor release.

On a positive note, 8% of adults 65+ say they got the booster in (approx) 3 weeks since its release, and close to 40% more say they plan to get it as soon as possible.
The groups among fully vaccinated adults most likely to express they aren’t sure if the bivalent booster is recommended for them include: rural residents (54%), Hispanic adults (51%), and those without a college degree (49%).
Read 5 tweets
Oct 6, 2021
Wonderful: a malaria vaccine is now recommended for use in high burden areas, and could save tens of thousands of lives a year
who.int/news/item/06-1…

(For sense of the timing: initial Phase 3 trial results for this vaccine were published a decade ago!)
nejm.org/doi/10.1056/NE…
WHO and others careful to note the vaccine is best positioned as one component of a comprehensive public health approach to malaria prevention. It is burdensome (4 shots over 18 months) and perhaps 50% effective in preventing severe malaria in kids.
Unclear how quickly it can be rolled out in African countries given the resources focused on Covid-19 vaccine distribution.

“We’re really going to have to see how the pandemic unfolds next year in terms of when countries will be ready"
nytimes.com/2021/10/06/hea…
Read 6 tweets
Oct 6, 2021
In 2022, protein-based COVID-19 vaccines could be what mRNA vaccines have not been for many lower-income countries: accessible and relatively easy to manage. Slower out of the gate than other vaccines, there are now several candidates on the near horizon. 1/
They are refrigerator stable, have promising safety profiles, and efficacy that in many cases rivals mRNA vaccines. Protein vaccines are also readily scalable, with good prospects for technology transfer 2/
nature.com/articles/d4158…
Novavax, delayed for months with manufacturing and supply woes, recently filed for authorization in several countries and WHO for its protein-based vaccine. COVAX has already purchased more Novavax doses (900 M) than any other vaccine in its portfolio 3/
launchandscalefaster.org/covid-19/vacci…
Read 9 tweets
Oct 4, 2021
Over 7 billion Covid-19 vaccine doses have been produced globally to date, with >1.35 billion more doses produced each month now.

Sinovac and Sinopharm produce the greatest number of vaccines monthly, with Pfizer and AstraZeneca not far behind. 1/
By the end of this year the world is likely to produce over 12 billion vaccine doses of all vaccine types.

By June 2022 the number produced could reach double that – 24 billion doses (assuming all goes well, and it usually doesn’t) 2/
Even after reserving doses for boosters, Western countries are likely to accumulate large stockpiles of vaccines over the coming months, perhaps as many as 1.2 billion doses by the end of this year.

These “surplus” doses could be redistributed to lower income countries. 3/
Read 7 tweets
Aug 25, 2021
Keeping a wary eye on Covid trends in South America. The good: cases/deaths there have come down from devastating peaks a few months back, and there’s progress on vaccinations. The bad: Delta may have only begun to circulate, and questions about vaccine efficacy
Most countries in the region have fully vaccinated between 20 and 40% of their populations; Chile and Uruguay stand out, with >70% fully vaccinated. Countries use a mix of vaccines, mostly Chinese inactivated vaccines (Sinovac and Sinopharm), plus some Pfizer & AstraZeneca
Chinese vaccines have lower effectiveness vs symptomatic disease but protect vs hospitalizations and death.
Chile estimated the Sinovac VE vs. symptomatic Covid at 58%, and 86% vs hospitalization. For Pfizer: 88% and 97%, AZ: 68% and 100%, respectively
minsal.cl/wp-content/upl…
Read 11 tweets
Aug 23, 2021
Some initial thoughts on full FDA approval of the Pfizer vaccine and what it might mean for vaccine acceptance in the US, based on @KFF polling and policy work
A commonly referenced finding from KFF's vaccine monitor is that 3 in 10 unvaccinated people reported they'd be more likely to get the vaccine upon full FDA approval
kff.org/coronavirus-co…
Still, I don't think it means that if unvaccinated people hear the news about full FDA approval 3 in 10 of will all of a sudden decide to get the shot based on that alone.
Read 8 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(